Abstract Carriers of cytogenetically similar, apparently balanced familial chromosome translocations not always exhibit the putative translocation-associated disease phenotype. Additional genetic defects, such as genomic imbalance at breakpoint regions or elsewhere in the genome, have been reported as the most plausible explanation.
Introduction
There is an intriguing group of apparently balanced familial chromosomal translocations characterized by phenotypic inconsistency among carriers of cytogenetically similar rearrangements.
The most fascinating explanation for this would be the co-inheritance of the chromosomal translocation with a mutation at the same or at a distinct genetic locus, leading to a recessive monogenic or digenic disorder. Such a case
has not yet been described so far (Sch€ affer 2013). On the contrary, genomic imbalance at breakpoint regions is the most plausible explanation of such phenotypic inconsistency observed among carriers of similar chromosomal translocations (De Gregori et al. 2007) .
Presently, the lack of a fully annotated human genome, including a haploinsufficiency map, hinders predictability of the phenotypic consequences of balanced chromosomal translocations even when the breakpoints are identified at nucleotide resolution. Although these may considerably affect the genomic architecture at breakpoint regions, a large majority are expected to be phenotypically imperceptible or subclinical. Nevertheless, otherwise subclinical translocations may modulate clinical phenotypes.
In eukaryotes ATP synthesis relies on glycolysis and oxidative phosphorylation (OXPHOS). Phosphoglycerate kinase 1 (PGK1; ATP: 3-phosphoglycerate 1-phosphotransferase; EC 2.7.2.3) is a multifunctional protein with a key role in ATP generation during glycolysis. PGK1 deficiency (OMIM #300653) is an X-linked recessive condition characterized by variable clinical manifestations involving up to three different tissues, i.e., red blood cells (RBC), skeletal muscle, and neurological tissue. However, patients rarely show all three clinical features (Beutler 2007; Chiarelli et al. 2012 ). To date, 22 different mutations have been identified in PGK1, and 17 of them have been characterized at the protein level Fermo et al. 2012; Tamai et al. 2014) .
Mitochondrial complex I (CI) or NADH-ubiquinone reductase (EC 1.6.5.3) is part of the electron transport chain that results in ATP synthesis through complex V or ATP synthase of the OXPHOS pathway (Fassone and Rahman 2012) . At least 12 assembly factors are required for the proper assembly, stability, or maturation of this CI (Fassone and Rahman 2012) . One of these assembly factors is NUBPL, the depletion of which causes CI deficiency (OMIM #252010) (Tucker et al. 2012; . Incorporation of Fe/S clusters into CI subunits by NUBPL is indispensable for electron transfer activity of CI (Sheftel et al. 2009 ).
Here we present detailed molecular and functional analyses demonstrating that the phenotype allegedly associated with the chromosome rearrangement t(3;14)(q26.33; q12) is actually due to a novel PGK1 variant, p.E120K, resulting in severe decrease of enzyme activity and that 14q12 breakpoint disruption of mitochondrial CI assembly factor, NUBPL, presumably exacerbates the neuromuscular symptoms of the enzyme deficiency.
Materials and Methods

Samples, Cytogenetic Analysis, and Lymphoblastoid Cell Lines (LCLs)
The family under study is from Hungary. Blood samples were collected after informed consent; the study was carried out according to the Principles of the Declaration of Helsinki of the World Medical Association.
Cytogenetic analyses and the establishment of LCLs were performed as previously described (David et al. 2009 ).
DNA extraction, flow sorting of derivative (der) chromosomes, array painting, amplification of the junction fragments, and SNP 6.0 array analysis Genomic DNA extractions, flow sorting, and amplification of der chromosome-specific DNAs were performed as described earlier (David et al. 2009 (David et al. , 2013 . Genomic amplicons of der(3) and der(14) chromosomes were analyzed by array painting using CytoScan HD array (Affymetrix, Santa Clara, CA, USA). The der(3) and der (14) junction fragments were amplified (see Table S1 for conditions) and sequenced by Sanger sequencing.
Genomic DNA from the index subject and his brothers (III:3 and III:6) was analyzed by Genome-Wide Human SNP 6.0 array (Affymetrix). Genotype calling was carried out using Genotyping Console software, and data was visualized using the Chromosome Analysis Suite (ChAS) software (Affymetrix).
Whole-Exome Sequencing (WES)
Exonic targets were captured and enriched using the SureSelect Human All Exon 50 Mb Kit from Agilent Technologies (Santa Clara, CA, USA) and sequenced on a HiSeq2000 instrument (Illumina, San Diego, CA) following the manufacturer's instructions. Variants were annotated, and known SNPs as well as novel genetic alterations were identified.
RNA Extraction and Expression Studies
Extraction of RNA samples from LCLs and reverse transcription (RT) reactions were performed as described earlier (David et al. 2013) . For real-time quantitative PCR (RT-qPCR), see supplementary material.
Expression profiling of LCLs from the index subject and III:3 was carried out using the Human Gene 1.0 ST expression array (Affymetrix), and data analysis was performed as previously described (David et al. 2013 ).
Construction of the Expression Vector Coding for PGK1 p.E120K Variant
The vector encoding PGK1-E120K variant was obtained by subjecting pMM1 to site-directed mutagenesis using Quick Change XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) . Mutagenic oligonucleotides are available in supplementary material.
Expression, Purification, and Characterization of the PGK1-E120K Variant The PGK1-E120K was expressed in E. coli BL21(DE3) pLysS cells grown on ZYP-5052 autoinducing medium. The expressed enzyme variant was purified essentially as previously described . Enzymatic activity and kinetic and thermal stability analyses have been performed (see the supplementary material).
SDS-PAGE and Immunodetection
SDS-PAGE analysis was performed in control and subjects' LCL's pellets (15 mg protein). For immunodetection the following antibodies were used: rabbit anti-NUBPL (Mitosciences, Eugene, OR, USA), mouse anti-tubulin (Sigma, St. Louis, USA), and MitoProfile Total OXPHOS antibody cocktail (Mitosciences, Eugene, OR, USA). Quantification was performed using the Quantity One (BioRad) software.
Results
Clinical Report
The first reported symptom of the index subject (Fig. 1 , III:5) was neonatal hyperbilirubinemia. Transfusion therapy was necessary at the age of eight months because of severe anemia, jaundice, and hepatomegaly, leading to the diagnosis of idiopathic hemolytic anemia. His dysmorphic features resembled those of his affected brother III:4 (Supplementary Material and Table S2 ), but, additionally, brachycephaly, short neck, reduced length of phalanges, four-digit crease on the right palm, cutaneous syndactyly II/III of the feet, and severe hypotonia were also reported (Fig. S2C) . Repeated therapy-resistant seizures started at one year of age, and his unconscious stage resulted in a suspected but unconfirmed diagnosis of meningoencephalitis. Besides epilepsy, one of the hemolytic events caused stroke and hemiparesis of the left side. Cognitive and somatic development of the child stopped at the age of one year and 6 months: he did not walk and could not speak, but he had no hearing loss. Swallowing difficulties became more and more pronounced; gastrostoma and tube feeding were initiated from the age of 2 years. Severe recurrent hemolytic crises led to a partial splenectomy at the age of four and a half years. Positron emission tomography revealed Rasmussen's encephalitis at 5 years of age. At 6 years of age, ketogenic diet was initiated.
At the age of thirteen years, in 2013, he presented total body muscle atrophy, generalized somatic hypotrophy, diminished joint movements, muscle contractures, severe somato-mental retardation, no speech and no personal contact with other individuals, multiple dental caries, and bilateral cryptorchidism. The eyes are "swimming."
Two of his brothers (Fig. 1 , III:3 and III:6) are healthy. In general, psychomotor development of III:3 was normal.
He did not present any dysmorphic features. Reportedly, with physical effort, he shows signs of weakness and premature fatigue, well before his age-matched coworkers (Table 1) .
Both parents are healthy, but the mother (II:5), in addition to anemia during pregnancies, also presents signs of fatigue.
During the course of this study, a maternal male cousin (Fig. 1, III: 2), who died after falling down the stairs at the age of 7 years, was reported to have symptoms similar to his cousins.
His mother (II:3) and the remaining relatives (I:2, II:1, III:1) are all healthy. For additional clinical description, including subjects III:4 and III:2, see supplementary material.
Cytogenetic Analysis
Cytogenetic analysis of GTL-banded metaphase chromosomes performed on subject III:4 revealed an apparently balanced reciprocal chromosome translocation between the long arms of chromosomes 3 and 14 [46, XY, t(3; 14)(q26.3; q12) ] (Fig. S2A and B) . Furthermore, his healthy mother (II:5) and two of his brothers (III:3 and III:5) were also carriers of a similar translocation (Fig. 1a) .
No perfect co-segregation between the translocation and the reported phenotype could be observed; therefore, we hypothesized that an additional genomic or genetic defect might also segregate in this family.
Breakpoints and Candidate Genes
Genomic amplicons of flow-sorted der chromosomes were analyzed by array painting, and the breakpoints were narrowed to few kb regions (data not shown). Primers flanking the predicted breakpoints were designed, and the junction fragments were amplified and sequenced (Table  S1 ). The alterations revealed by sequence alignments of the junction fragments are summarized in Fig. S1 . The 3q26.33 breakpoint is at position g.180,278,286_ 180,278,294delTTCTGCA, 41.6 kb upstream of the 5 0 region of tetratricopeptide repeat domain 14 (TTC14), a gene whose function is presently unknown (Fig. S3) . Additional genes localized further distal from the breakpoint are (1) the coiled-coil domain containing 39 (CCDC39) localized only at 53.5 kb, (2) the FXR1, and (3) the DnaJ (Hsp40) homologue, subfamily C, member 19 (DNAJC19). This gene encodes an important protein for mitochondrial physiology. Located at the inner mitochondrial membrane, it has been shown to function as a chaperone for mitochondrial protein import system. Defects in this gene are reported to cause an autosomal recessive secondary 3-methylglutaconic aciduria (OMIM #610198), a disorder that partially overlaps with that of reported subjects (Table 1) (Wortmann et al. 2012 (Wortmann et al. , 2013  Davey et al. 2006) . Therefore, serum and urine amino acid and urine organic acid levels were determined (see Table  S3A and S3B). In subject III:3, 3-hydroxybutyric acid was especially increased, but also 3-methylglutaconic acid (3-MGA) and 3-methylglutaric acid (3-MG) were slightly increased. The 14q12 breakpoint is at position g.32,248,943_ 32,248,944dupATAAGATAACAAG, within IVS6 of NUBPL (Fig. 2) , a member of the Mrp/NBP35 ATPbinding protein family, and critical for the assembly of human respiratory mitochondrial CI (Sheftel et al. 2009 ). Recently, recessive mutations in NUBPL have been implicated in the genetic etiology of CI deficiency [OMIM #252010], a mitochondrial respiratory chain defect that is caused by mutations in multiple different nuclear, mitochondrial, or X-linked genes (Calvo et al. 2010; Fassone and Rahman 2012) . Additionally, in subjects with pediatric neurological disorders, three deletions encompassing this gene were reported (p ¼ 0.135) (Cooper et al. 2011 ).
Exclusion of Genomic Imbalance and Identification of the Additional Genetic Defect
Pathogenic genomic imbalance that could explain the phenotypic inconsistency observed among translocation carriers was excluded by SNP 6.0 array analysis.
Subsequently, reevaluation of the family history revealed that the maternal cousin (III:2; Fig. 1a ) presented a clinical phenotype resembling that of index subject. Based on this, two possible disorders, X-linked PGK1 and triosephosphate isomerase 1 (TPI1; OMIM #190450, 12p13.31) deficiencies, were suggested. Furthermore, X-chromosome segregation analysis among siblings using array-based SNP data corroborated the possibility of PGK1 deficiency (data not shown). Consequently, WES of the index subject revealed a novel missense mutation c.358G>A that leads to a change from glutamic acid to lysine at position 120 of PGK1 (p.E120K) within exon 4 (Fig. 1b) . Segregation study confirmed this alteration in the index subject and showed that female subjects I:2, II:3, and II:5 are asymptomatic carriers (Fig. 1a , c and d), whereas the remaining family members are normal. Substitution of the highly conserved, solvent-exposed, negatively charged glutamic acid 120 by positively charged lysine (E120K; Table S7, Figs. S4 and S7) increases the net charge of the protein by two units (from 2.8 to 4.8 at pH 7.4) and certainly strongly argues in favor of this being the disease-causing mutation.
Borderline skewed X-chromosome inactivation toward the normal allele (25:75) was observed in female II:5, the only mutation carrier that presented symptoms during pregnancy (data not shown).
Functional Characterization of the PGK1 p.E120K Variant
The specific activity of the purified PGK1-E120K variant was 10.2 U/mg compared to that of 816 U/mg of PGK1-WT .
Kinetic analysis showed that, like PGK1-WT, PGK1-E120K variant was activated by high substrate concentrations ( Fig. 3a and b) . The mutant enzyme turned out to be severely affected in its kinetic properties (Table S4) , showing a reduction of two orders of magnitude of its apparent k cat values toward both substrates. The apparent K m value toward 3-PG was sevenfold increased with respect to that of PGK1-WT, whereas that toward Mg-ATP was practically unchanged.
Interestingly, the variant's thermal inactivation rate curve was biphasic, with an increased slope after 5 min incubation, suggesting that it underwent heat-induced molecular change leading to the loss of enzyme activity (Fig. S5 ).
Gene Expression Studies
Expression array profiling of LCLs from translocation carriers (only one of them affected by the PGK1 mutation) did not reveal significantly altered expression of genes from the breakpoints (Table S5 ). The expression level of the disrupted NUBPL was only reduced by~1 SD.
Subsequently, expression levels of three of these genes were also analyzed in subjects II:5, III:5, III:3, III:6, and controls by RT-qPCR (Fig. 4a, Table S5 , Fig. S6A and B) . By this analysis, a statistically significant 2.6-fold reduction of the NUBPL expression level (P ¼ 0.0001; 0.061 vs. 0.156) was observed.
Additionally, systematic analysis of array expression data of mitochondrial CI subunits did not show considerable alteration in their expression (Table S6) .
SDS-PAGE Western Blot Analysis
Levels of the five OXPHOS complexes as well as the NUBPL assembly factor were determined by SDS-PAGE Western blot in LCLs, as our attempt to establish a fibroblast cell line from the index subject was unsuccessful.
NUBPL levels were reduced in all translocation carriers although at different extent (Fig. 4b) . No significant changes were observed in the levels of the five complexes Fig. 3 Kinetic profile of PGK1-E120K variant vs. wild-type enzyme. Steady-state kinetics of PGK1-E120K variant and wild-type as function of (a) Mg-ATP at fixed 5 mM 3-PG concentration and (b) as of 3-PG at fixed 5 mM Mg-ATP concentration. Open circles represent the PGK1-E120K variant, whereas filled circles represent the wild type. Like the wild type, the PGK1-E120K variant presents a biphasic kinetic behavior toward the two substrates; therefore, the linear region (0-5 mM substrates, range of physiological concentration) was considered to extrapolate the kinetic parameters by the OXPHOS antibody cocktail (Fig. 4c) . The dissimilar reduction of NUBPL protein in translocation carriers is in striking contrast with the evenly reduced mRNAs levels (Fig. 4a) .
Discussion
Alleged association of the familial translocation t(3;14) (q26;q12) with a particularly severe hemolytic anemia and neuromyopathy led us to map the translocation breakpoints, at nucleotide resolution.
Given the absence of genomic imbalance that could explain the phenotypic inconsistency observed among translocation carriers, and taking into account previously unreported family medical history data, the presence of an additional genetic defect was hypothesized. Segregation analysis of X chromosome and WES revealed that the index subject is also affected by a novel X-linked PGK1 mutation (c.358G>A, p.E120K) within a highly conserved region.
Biochemical and functional characterization of the PGK1-E120K variant showed highly perturbed kinetic properties (Table S4) . Very likely the p.E120K substitution leads to a distorted local protein structure with detrimental indirect effect on the active site geometry, locking the enzyme in a more tight conformation and hindering proper domain movements required for its catalytic activity. Additionally, the variant turned out to have weakened protein stability (Fig. S4 ) most likely due to an intrinsic propensity of aggregating in a temperature-and timedependent manner (Pey et al. 2013) . These data led us to conclude that p.E120K is one of the most severely impaired PGK1 variants characterized thus far Chiarelli et al. 2012 ) and consequently the main genetic cause of the phenotype observed in this family.
Although rare, lethal forms of PGK1 deficiency during infancy have been reported in the literature (Beutler 2007) . Even more infrequent are PGK1-deficient patients exhibiting the three distinguishing clinical features of this deficiency (hereditary non-spherocytic hemolytic anemia, neurological dysfunction, and myopathy). In the family reported here, all affected subjects (III:2, III:4, and III:5) presented the full clinical spectrum of PGK1 deficiency, and seemingly they are among the most severely affected PGK1-deficient patients reported to date.
The disruption of NUBPL by the 14q12 breakpoint led to a 60% reduction of the mRNA expression level of this CI assembly factor in three family members. Concomitant reduction of the protein level was also observed, being the index subject, the most affected one. The translocation per se is only associated with a subclinical state as the only clinical feature reported in translocation carriers (without PGK1 deficiency) is exercise intolerance due to premature fatigue, a common symptom of mitochondrial myopathy.
Interestingly, homozygous subjects for the branch-site mutation c.815-27T>C within IVS 9 of NUBPL are predicted to have~30% of NUBPL expression. This mutation was excluded in the presently reported family (data not shown). The partially impaired CI function in these subjects is also sub-pathologic and certainly not associated to a mitochondrial CI disease (Tucker et al. 2012) .
Although generally the clinical phenotype of family members carrying identical PGK1 mutations is reportedly similar, both translocation carriers (III:4 and III:5), unlike their translocation noncarrier cousin, show severe neuromyopathy with exacerbated muscular dystrophy.
In different tissues or pathogenic conditions, one of the two metabolic pathways, glycolysis or OXPHOS, is predominant over the other (Hu et al. 2012) . Additionally, these pathways are interconnected as cytosolic NADH, the electron supplier that drives ATP synthesis via OXPHOS, is generated through glycolysis to pyruvate by glyceraldehyde-3-phosphate dehydrogenase (GAPDH) [see Glycolysis: Regulating Blood Glucose, http://themedicalbiochemistrypage.org/glycolysis.php] (Ramzan et al. 2013) . Synergistic interactions, called synergistic heterozygosity, between defects in one or more different energy metabolism pathways have been reported as a common disease mechanism (Vockley et al. 2000) . Such interaction between the reported genetic defects, both participating in cellular energy metabolism, seems obvious.
Although unlikely, we cannot exclude that other genes from the breakpoint regions, such as DNAJC19, may also contribute to the increased clinical severity of PGK1 deficiency in translocation carriers. The slight increase of both 3-MGA and 3-MG observed in the index subject can be related with several features of the clinical phenotype (metabolic disorder, mitochondrial dysfunction, progressive neuromuscular degeneration, and anemia) (Wortmann et al. 2013) . Additionally, glycogen granules and granular structures in the mitochondria of endothelial cells and muscle fibers were reported in a PGK1-deficient subject (Schr€ oder et al. 1996) . Therefore, involvement of PGK1 deficiency in mitochondrial dysfunction seems likely and can also be related to the drastic reduction of NUBPL in the index subject.
Even more unlikely, but theoretically possible, is that the observed phenotype is exclusively the result of the novel PGK1 mutation, and the phenotype heterogeneity observed among translocation carriers and noncarriers is the outcome of each individual's genomic/epigenetic background.
In conclusion, the discordant inheritance of the allegedly translocation-associated severe phenotype, instead of being due to a genomic imbalance, is mainly explained by independent inheritance of a novel PGK1 c.358G>A, p. E120K mutation. The pathogenicity of this mutation was confirmed by in vitro functional characterization of the variant. Furthermore, the t(3;14)(q26;q12) is only associated with a subclinical phenotype; nevertheless, disruption NUBPL, a component of the OXPHOS cellular energy pathway, most likely exacerbates the PGK1-deficient phenotype in subjects who are also translocation carriers. In addition, the case presented here constitutes a "beautiful" example of synergistic heterozygosity and a naturally occurring model to study the interactions between cellular energy pathways and their association with mitochondrial dysfunction. Therefore, further studies are warranted to clarify these additional aspects.
Additionally our data imply that synergistic interactions, involving heterozygous genomic and chromosome rearrangements, may contribute for the "missing" heritability of inborn metabolic disorders. Last but not least, this study eloquently illustrates that even in our genomic era with WES and personalized genomics, a thorough family medical history is necessary in the elucidation of the molecular bases of rare diseases and their prevention.
Synopsis
An extremely severe non-spherocytic hemolytic anemia and neuromyopathy, hypothesized to be associated with chromosome translocation-associated genomic imbalance, were shown to be mainly caused by a novel pathogenic severe PGK1 mutation and that the neuromyopathic symptoms of the deficiency are likely exacerbated by the disruption of mitochondrial complex I assembly factor, NUBPL.
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Analysis of WES, amplification and segregation analysis of the PGK1 mutation
Mapping of the sequence reads was carried out by the Burrows-Wheeler Alignment tool (BWA) (Li and Durbin, 2009 ). For identification of single-nucleotide variants (SNVs) and small insertions / deletions the BWA alignment output SAM file (Sequence Alignment/Map) was further analyzed by SAMtools software package (Li et al, 2009 ). Amplification of PGK1 (RefSeq NM_000291.3) exon 4 from genomic DNAs was carried out using primers described in Table S1 .
Confirmation of the novel PGK1 mutation identified by WES and segregation analysis in available family members was performed by Sanger sequencing as described earlier (David et al, 2009 ).
X-chromosome inactivation assay X-chromosome inactivation patterns in female carriers of the PGK1 mutation were assayed according to Kiedrowski and co-workers (Kiedrowski et al, 2011) .
Gene expression studies by real-time quantitative PCR (RT-qPCR)
Expression level of three genes from the breakpoint regions were also analyzed using TaqMan gene expression assays. Namely, assay Hs00228512_m1, for exon 8 to 9 junction of the disrupted NUBPL; assay Hs00750732_s1, for exon 2 of Rho GTPase activating protein 5 (ARHGAP5) and assay Hs01096865_m1, for exon 2 to 3 junction of fragile X mental retardation, autosomal homolog 1 (FXR1). Death inducer-obliterator 1 (DIDO1; assay Hs00223101_m1) was used as internal control.
All RT-qPCR reactions were performed in triplicate on an ABI 7000 Sequence Detection System (Applied Biosystems, Foster City, USA). The system's default PCR conditions were used with 40 cycles. Data and statistical analysis were performed as previously described (David et al, 2013) .
Expression, purification and characterization of the PGK1-E120K variant
The following mutagenic oligonucleotides were used : 5' CTGTCATCCTGCTGAAGAACCTCCGCTTTC 3' and 5' GAAAGCGGAGGTTCTTCAGCAGGATGACAG 3', respectively (the mutated nucleotides are underlined). The variant cDNA was completely sequenced.
In order to remove protein aggregates, from the purified enzyme variant, a size exclusion chromatographic step on a 16/60 Superdex 75 column (GE Healthcare, Buckinghamshire, UK) equilibrated with 20 mM Tris pH 8.0, 1 mM EDTA, 2mM β-mercaptoethanol, 200 mM NaCl was included Pey et al, 2013) .
The enzyme activity of PGK1-E120K was measured at 37°C by glyceraldehyde 3-phosphate dehydrogenase (GAPDH)-coupled spectrophotometric assay following the method recommended by the International Committee for Standardization in Hematology . The standard reaction mixture contained 100 mM Tris pH 8.0, 0.5 mM EDTA, 2 mM MgCl2, 0.24 mM NADH, 0.4 µM GAPDH, 5 mM Mg-ATP and 5 mM 3-phosphoglycerate (3-PG), in a final volume of 0.5 ml. The reaction was started by adding enzyme solution (0.1-0.5 µg).
Kinetic analyses were performed by assaying the enzyme activity at ten different concentrations of 3-PG and Mg-ATP in the presence of 5 mM Mg-ATP and 5 mM 3-PG, respectively. The reaction conditions were identical to those described above. All measurements were performed in triplicate by using a Jasco V-550 UV/VIS spectrophotometer (Jasco, Cremella, Italy). Kinetic parameters were calculated as previously described using SigmaPlot software version 12.0 (IBM SPSS, Inc., Chicago, IL, USA) (Szilágyi and Vas, 1998) .
For thermal stability studies, residual enzyme activity was assayed at different timepoints after incubation of purified enzyme (0.7 mg/ml) at given temperatures .
SDS-PAGE and immunodetection
Control and subjects' LCL's pellets were lysed in 200 μl homogenization buffer (150 mM NaCl, 1% NP-40 and 5 mM Tris/HCl, pH 8.0). Equal amounts of protein (15 μg) and a Precision Plus Protein Standards (BioRad, Hercules, CA, USA) were loaded and separated in SDS-PAGE gels (NuPAGE Novex 4-12% Bis-Tris gels; Invitrogen, Carlsbad, CA, USA). Gels were blotted to a PVDF transfer membrane (Immobilion-P, Millipore, Tullagreen, Ireland). Membrane was blocked with 5% skimmed milk and 0.05% Tween-20 in Trisbuffered saline (TBS) for 1 h at room temperature and incubated with primary antibodies, 2h, at room temperature. The following specific antibodies were used: rabbit anti-NUBPL, (Mitosciences, Eugene, OR, USA), mouse anti-tubulin (Sigma, St. Louis, USA) and MitoProfile Total OXPHOS antibody cocktail containing antibodies against: complex I subunit NDUFB8, complex II subunit 30 kDa, complex III subunit Core 2, complex IV subunit II and ATP synthase subunit alpha (Mitosciences, Eugene, OR, USA). Membranes were then washed three times with 0.05% Tween-20 in TBS, incubated with the appropriate peroxidase-conjugated IgGs secondary antibodies (GE Healthcare) for 1 h at room temperature and developed using Clarity Western ECL Substrate (BioRad). Quantification was performed using the software Quantity One (BioRad).
Results
Clinical reports
Subject III:4 (Fig. 1 ) Subject III:4 (Fig. 1A) is the first known affected case in the family, the second (male) child of unrelated, apparently healthy parents. The newborn presented with hepato-splenomegaly and erythroblastosis fetalis, with a mild jaundice that did not require any exchange transfusion. At the end of the first week, generalized spastic muscle tone, nuchal and dorsal muscle hypotonia were observed.
First hospital admission occurred at the age of one and a half months because of severe anemia, requiring blood transfusions. At the age of two months, the following dysmorphic signs were observed: moderate microcephaly, hypertelorism, epicanthal folds, broad nasal bridge, high arched palate, asymmetric face, fronto-occipital cranial elongation, low-set ears, short and pointed nose, frontal bossing, (see Table S2 ). Repeated infections of the respiratory tract, hemolytic episodes and severe general dystrophy during the first year of life made hospital admissions and blood transfusions at every second month necessary. Tonic-clonic seizures occurred for the first time at the age of twenty months. The neurological evaluations led to diagnosis of epilepsy. Increased muscle tone, especially of lower limbs and permanent horizontal nystagmus were obvious. He never sat up or walked and his weight gain stopped. Epileptic seizures became more and more frequent and he had difficulties in swallowing therefore tube feeding was initiated. He died at the age of four and a half years.
Peripheral blood cell analysis revealed low red blood cells (RBC) count (1.9×10 12 /L), hematocrit (HCT: 0.20) and decreased hemoglobin (61 g/L). Mean corpuscular volume (MCV) was decreased (65μm 3 ), whereas mean cell hemoglobin (MCH) and mean corpuscular hemoglobin concentration (MCHC) values were in normal range. Reticulocyte count was 98 ‰. Bone marrow contained normal amount of cells with slightly increased erythropoiesis and normal myelopoiesis. Coombs test and hemoglobin electrophoresis, were found as normal. Serum iron, ferritin levels, as well as total iron-binding capacity (TIBC), serum and erythrocyte folate and vitamin B12 levels were as in age-matched controls. Based on shorter erythrocyte lifespan (26 days), decreased osmotic resistance (0.40) and increased permeability, the diagnosis of intrinsic hemolytic anemia was established.
In this period, significant decrease of plasma alkaline phosphatase activity, 10 IU/L, was observed (normal range for child 50-100 IU/L).
Cardiovascular malformation and pathologic meningeal symptoms were not detected. Diagnostic imaging methods did not reveal any structural abnormality of the brain. Index subject III:5 (Fig. 1 ) Blood tests repeatedly showed major increase in creatine phosphokinase (CPK), 60,000 IU/L (normal range for children 50-100 IU/L) as well as of lactate dehydrogenase (LDH), 5,000 U/L, (normal range for children 154-605). At 6 years of age ketogenic diet was initiated.
Cardiac echography and ECG, as well as abdominal ultrasonography resulted in normal findings. No pathologic alteration could be found by audiometric hearing tests. At 11 years of age, sex hormone levels are similar to age-matched prepubertal boys. Subject III:2 (Fig. 1) After the parents' informed consent, his hospital records were studied. Indeed, he presented mental retardation, severe hemolytic anemia and seizures. Repeated infections and hemolytic crisis required frequent hospitalization and blood transfusions. At two years of age, he was treated for encephalopathy and liver damage. At six years of age, neurological evaluation was done because of coma and clonic-tonic seizures, resulting in diagnosis of therapy-resistant epilepsy. Owing to swallowing difficulties tube feeding was also initiated from the age of two years. There was a main difference compared to his cousins; he was able to walk with help and he presented generalized edema throughout the whole body. His mother (II:3), although operated because of a thrombotic accident, is healthy. The remaining relatives (I:2, II:1, III:1) are also healthy.
Normal findings have been reported at cardiac examination and echocardiography. Figure S1 . Nucleotide sequence of der(3) and der(14) breakpoints aligned against the reference sequence. (A) Derivative chromosome 3 breakpoint. The chromosome 3 sequence is in black, whereas of chromosome 14 in gray. Vertical lines indicate identical nucleotides between derivative and reference chromosomes. The seven nucleotide (TTCTGCT) deletion from the chromosome 3 sequence is boxed, whereas the dinucleotide insertion (AG) at the der(3) breakpoint is in blue lowercase letters. (B) Derivative chromosome 14 breakpoint. The a 13 bp duplication (ATAAGATAACAAG) is in blue lowercase letters; the homologous sequence is underlined with solid and dotted lines, whereas those (GACTT) between chromosomes 3 and 14 (GACTT) by double line (reference human genome assembly GRCh37/hg19 (Ordulu et al, 2014) . NCBI-GenBank accession numbers of the junction fragment sequences are KJ862055 and KJ862056, respectively. (C) Clinical details of the index subject (III:5) -moderate microcephaly, short neck, frontooccipital cranial elongation, frontal bossing, asymmetric face, hypertelorism, "swimming" eyes, epicanthal folds, broad nasal bridge, short nose, low-set dysplastic ears, total body muscle atrophy, muscle contractures, multiple dental caries (see Table S2 ). Figure S4 . Alignment of the human PGK1 peptide sequence containing the amino acid substitution E120K with corresponding region of PGK from different species. The amino acid numbering of PGK1 starts with methionine. The dark grey zone indicates highly conserved region containing the mutated residue E120K (↓) and the 3-PG substrate binding residue R123 (○), just three amino acids downstream from the mutated one (Vas et al, 2010) . Residue E120 is located on the short loop that follows β-strand D (Fig. S7) . Residues belonging to the β-strand D are indicated by the black rectangle. Figure S5 . Thermal stability of wild-type and variant PGK1. Heat stability of PGK1-E120K variant (□) at 37°C and 45°C compared to wild-type enzyme (○). Thermal stability was measured by incubating the enzyme (0.7 mg/ml) at the given temperatures in a solution consisting of 20 mM Tris pH 8.0, 1 mM EDTA, 2mM β-mercaptoethanol. Samples (10 µl) were removed at intervals, chilled in ice and immediately assayed according to the published method . Relative activity was calculated as the percent of the enzyme activity before the incubation. Fill symbols represent data points obtained at 37°C, open symbols at 45°C. The mutant enzyme lost 50% of its activity after 36 minutes of incubation at 37°C, whereas at 45°C the half time was nearly 6 min. The variant's thermal inactivation rate at 45°C accounts for an increased heat induced aggregation, as supported by the fact that samples treated at 45°C become more turbid with time. On the other hand, the freshly purified enzyme formed aggregates just after few hours of storage at 4°C. (Balog et al, 2007) . Alpha-helixes are represented as cartoon in red while beta-sheets are in blue; Mg-ADP and 3-PG are shown as black stick models. a Numbers indicate the position of the primers in the current genome assembly (GRCh37/hg19). . CCDC39, OMIM #613807; an autosomal recessive primary ciliary dyskinesia (PCD) characterized by: neonatal respiratory distress, chronic infections of the respiratory tract, rhinosinusitis, situs inversus, situs ambiguous or Kartagener's syndrome, sperm dysmotility or goasthenospermia and infertility (Antony et al, 2013; Merveille et al, 2011) . DNAJC19, OMIM #610198, 3-methylglutaconic aciduria, type V (MGCA5); an autosomal recessive disorder named dilated cardiomyopathy with ataxia (DCMA) characterized by: increase (5 to 10 fold) in urine 3-methylglutaconic acid (3-MGC) and 3-methylglutaric acid (3-MGA), early-onset dilated cardiomyopathy, long QT syndrome, ECG abnormalities, prenatal or postnatal growth failure, non-progressive cerebellar ataxia causing significant motor delays, testicular dysgenesis, isolated cryptorchidism to severe perineal hypospadias; normochromic microcytic anaemia, mental retardation and increase in hepatic enzymes and liver steatosis (Wortmann et al, 2012) . Determination of serum and urine amino acid levels was carried out by liquid chromatography / mass spectrometry (LC/MC) using the EZ:Fast amino acid analysis kit (Phenomenex, Torrance, CA, USA). Samples 1 and 2 of index patient were collected with three months interval during ketogenic diet and sample 3 after suspension of ketogenic diet for 5 days. Age-matched reference values for serum and urine amino acids concentrations were established from healthy children within the age range of 6 to 12 and 8 to16 years, respectively. Amino acid levels in the mother are within the normal range of age-matched controls. Samp: sample; ND: not done. Urinary organic acid profiling was carried out by gas chromatography linked mass spectrometry (GC/MS) methodology after desalting, ethylacetate extraction and oximetrimethylsilyl derivatization of urine samples. Samples 1 and 2 were collected with three months interval. Age-matched reference values of healthy children within age range 6 -12 years. Samp: sample; ND: not done. Levels are expressed in mmol/mol creatinine. 
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